Hims & Hers Health (HIMS) Expected to Announce Earnings on Monday

Key Points

• Hims & Hers Health (HIMS) is set to report Q1 2026 results after the market close on May 11, with analysts forecasting $0.04 EPS and $616.9 million in revenue.
• The company beat estimates last quarter with $0.08 EPS and $617.8 million in revenue, a 28.4% year-over-year increase.
• Insiders have sold shares recently (204,857 shares, about $5.29M over three months), while analysts hold a consensus "Hold" rating and a target price of $32.53.

Hims & Hers Health (NYSE:HIMS - Get Free Report) is anticipated to release its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect Hims & Hers Health to post earnings of $0.04 per share and revenue of $616.8760 million for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 11, 2026 at 5:00 PM ET.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, February 23rd. The company reported $0.08 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The company had revenue of $617.82 million during the quarter, compared to analyst estimates of $619.48 million. During the same period last year, the business earned $0.11 earnings per share. Hims & Hers Health's revenue was up 28.4% compared to the same quarter last year. On average, analysts expect Hims & Hers Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Hims & Hers Health Price Performance

HIMS stock opened at $27.36 on Monday. The firm has a 50 day moving average of $21.91 and a 200-day moving average of $30.40. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80. Hims & Hers Health has a 12 month low of $13.74 and a 12 month high of $70.43. The firm has a market capitalization of $6.24 billion, a P/E ratio of 53.65, a price-to-earnings-growth ratio of 2.84 and a beta of 2.43.

Insider Activity

In related news, insider Irene Becklund sold 5,529 shares of Hims & Hers Health stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $136,511.01. Following the transaction, the insider directly owned 8,752 shares of the company's stock, valued at $216,086.88. The trade was a 38.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $25.90, for a total transaction of $956,279.80. Following the completion of the transaction, the chief financial officer directly owned 281,867 shares in the company, valued at approximately $7,300,355.30. The trade was a 11.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 204,857 shares of company stock valued at $5,285,706 in the last three months. Corporate insiders own 17.71% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in HIMS. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health in the third quarter worth $28,000. Geneos Wealth Management Inc. purchased a new position in shares of Hims & Hers Health in the first quarter worth $30,000. Greenline Wealth Management LLC purchased a new position in shares of Hims & Hers Health in the fourth quarter worth $36,000. DV Equities LLC purchased a new position in shares of Hims & Hers Health in the fourth quarter worth $46,000. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Hims & Hers Health by 273.7% in the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company's stock worth $47,000 after buying an additional 687 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on HIMS. Leerink Partners raised their price objective on shares of Hims & Hers Health from $17.50 to $25.00 and gave the company a "market perform" rating in a research report on Monday, March 16th. Evercore set a $24.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Zacks Research upgraded shares of Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research report on Wednesday, February 25th. BTIG Research lowered shares of Hims & Hers Health from a "buy" rating to a "neutral" rating in a research report on Tuesday, February 24th. Finally, Barclays raised their price objective on shares of Hims & Hers Health from $25.00 to $29.00 and gave the company an "overweight" rating in a research report on Wednesday, March 11th. Four equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Hims & Hers Health presently has a consensus rating of "Hold" and a consensus target price of $32.53.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.